Evaluating the Phase II drugs currently under investigation for diabetic neuropathy

Bibliography

• Diabetes Atlas. International Diabetes Federation. 5th edition. IDF, Brussels, Belgium; 2011
   Google Scholar
• Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci 2006;1084:1–29
   PubMed Web of Science ®Google Scholar
• Forbes LE, Fraser SN, Downs SM, et al. Changes in dietary and physical activity risk factors for type 2 diabetes in Alberta youth between 2005 and 2008. Can J Public Health 2013;104:e490–5
   PubMed Web of Science ®Google Scholar
• Abebe SM, Berhane Y, Worku A, et al. Diabetes mellitus in North West Ethiopia: a community based study. BMC Public Health 2014;14:97
   PubMed Web of Science ®Google Scholar
• Krogh-Madsen R, Pedersen M, Solomon TP, et al. Normal physical activity obliterates the deleterious effects of a high-caloric intake. J Appl Physiol 2014;116:231–9
   PubMed Web of Science ®Google Scholar
• Ning F, Pang ZC, Dong YH, et al. Risk factors associated with the dramatic increase in the prevalence of diabetes in the adult Chinese population in Qingdao, China. Diabet Med 2009;26:855–63
   PubMed Web of Science ®Google Scholar
• Pugliese G. Do advanced glycation end products contribute to the development of long-term diabetic complications? Nutr Metab Cardiovasc Dis 2008;18:457–60
   PubMed Web of Science ®Google Scholar
• Charnogursky G, Lee H, Lopez N. Diabetic neuropathy. Handb Clin Neurol 2014;120:773–85
   PubMedGoogle Scholar
• Deli G, Bosnyak E, Pusch G, et al. Diabetic Neuropathies: diagnosis and Management. Neuroendocrinology 2013;98(4):267–80
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012;28(Suppl 1):8–14
   PubMed Web of Science ®Google Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2010;380(9859):2163–96
   Web of Science ®Google Scholar
• Dias IH, Griffiths HR. Oxidative stress in diabetes - circulating advanced glycation end products, lipid oxidation and vascular disease. Ann Clin Biochem 2014;51:125–7
   PubMed Web of Science ®Google Scholar
• Teshima Y, Takahashi N, Nishio S, et al. Production of reactive oxygen species in the diabetic heart. Circ J 2014;78:300–6
   PubMed Web of Science ®Google Scholar
• Gao F, Zheng ZM. Animal models of diabetic neuropathic pain. Exp Clin Endocrinol Diabetes 2014;122:100–6
   PubMed Web of Science ®Google Scholar
• Feng B, Ruiz MA, Chakrabarti S. Oxidative-stress-induced epigenetic changes in chronic diabetic complications. Can J Physiol Pharmacol 2013;91:213–20
   PubMed Web of Science ®Google Scholar
• Fan YY, Kobori H, Nakano D, et al. Aberrant activation of the intrarenal renin-angiotensin system in the developing kidneys of type 2 diabetic rats. Horm Metab Res 2013;45:338–43
   PubMed Web of Science ®Google Scholar
• Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem 2004;261:187–91
   PubMed Web of Science ®Google Scholar
• Gardiner TA, Anderson HR, Stitt AW. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol 2003;201:328–33
   PubMed Web of Science ®Google Scholar
• Cameron NE, Eaton SE, Cotter MA, et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001;44:1973–88
   PubMed Web of Science ®Google Scholar
• Boulton AJM. Management of diabetic peripheral neuropathy. Clin Diabetes 2005;23:9–15
   Google Scholar
• O’Brien PD, Hinder LM, Sakowski SA, et al. ER stress in diabetic peripheral neuropathy: a new therapeutic target. Antioxid Redox Signal 2014;21(4):621–33
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33(10):2285–93
   PubMed Web of Science ®Google Scholar
• Vinik AI, Maser RE, Mitchell BD, et al. Diabetic autonomic neuropathy. Diabetes Care 2003;26:1553–79
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kögel B, et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265–76
   PubMed Web of Science ®Google Scholar
• Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76(20):1758–65
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 2013;36:2456–65
   PubMed Web of Science ®Google Scholar
• Bouhassira D, Letanoux M, Hartemann A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study. PLoS One 2013;8(9):e74195
   PubMed Web of Science ®Google Scholar
• Rekleiti M, Sarafis P, Saridi M, et al. Investigation of depression in Greek patients with diabetic peripheral neuropathy. Glob J Health Sci 2013;5:107–14
   PubMedGoogle Scholar
• Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ 2007;335(7610):87
   PubMed Web of Science ®Google Scholar
• Gilron I, Bailey JM, Tu D, et al. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial. Lancet 2009;374(9697):1252–61
   PubMed Web of Science ®Google Scholar
• Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012;12:CD008242
   PubMedGoogle Scholar
• Lee YC, Chen PP. A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother 2010;11:2813–25
   PubMed Web of Science ®Google Scholar
• Sultan A, Gaskell H, Derry S, et al. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol 2008;8:29
   PubMed Web of Science ®Google Scholar
• Lindsay TJ, Rodgers BC, Savath V, et al. Treating diabetic peripheral neuropathic pain. Am Fam Physician 2010;82:151–8
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2005;113:248
   Web of Science ®Google Scholar
• Argoff CE, Backonja MM, Belgrade MJ, et al. Diabetic peripheral neuropathic pain: consensus guidelines for treatment. J Fam Pract 2006;55(Suppl):1–19
   PubMedGoogle Scholar
• Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care 2008;31:1448–54
   PubMed Web of Science ®Google Scholar
• Waxman SG, Zamponi GW. Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci 2014;17(2):153–63
   PubMed Web of Science ®Google Scholar
• Available from: Clinicaltrials.gov/show/NCT01521598
   Google Scholar
• Desai B, Freeman E, Huang E, et al. Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy. Expert Rev Clin Pharmacol 2014;7:203–9
   PubMed Web of Science ®Google Scholar
• Games G, Hutchison A. Tapentadol-ER for the treatment of diabetic peripheral neuropathy. Consult Pharm 2013;28:672–5
   PubMedGoogle Scholar
• Vadivelu N, Huang Y, Mirante B, et al. Patient considerations in the use of tapentadol for moderate to severe pain. Drug Healthc Patient Saf 2013;5:151–9
   Google Scholar
• Available from: http://www.grunenthal.net/grt-oceanic/265600020.jsp
   Google Scholar
• Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain 2012;153:1815–23
   PubMed Web of Science ®Google Scholar
• van Rijn RM, Harvey JH, Brissett DI, et al. Novel screening assay for the selective detection of G-protein-coupled receptor heteromer signaling. J Pharmacol Exp Ther 2013;344(1):179–88
   PubMed Web of Science ®Google Scholar
• Nozaki C, Le Bourdonnec B, Reiss D, et al. δ-Opioid mechanisms for ADL5747 and ADL5859 effects in mice: analgesia, locomotion, and receptor internalization. J Pharmacol Exp Ther 2012;342:799–807
   PubMed Web of Science ®Google Scholar
• Wymer JP, Simpson J, Sen D, et al. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain 2009;25:376–85
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308–17
   PubMed Web of Science ®Google Scholar
• Stöhr T, Kupferberg HJ, Stables JP, et al. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007;74:147–54
   PubMed Web of Science ®Google Scholar
• Duncan GE, Kohn H. The novel antiepileptic drug lacosamide blocks behavioral and brain metabolic manifestations of seizure activity in the 6 Hz psychomotor seizure model. Epilepsy Res 2005;67:81–7
   PubMed Web of Science ®Google Scholar
• Ziegler D, Hidvégi T, Gurieva I, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care 2010;33(4):839–41
   PubMed Web of Science ®Google Scholar
• Deshpande LS, Nagarkatti N, Sombati S, et al. The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharges and blocking sustained repetitive firing in cultured hippocampal neurons. Epilepsy Res 2008;79:158–65
   PubMed Web of Science ®Google Scholar
• Cady RK, Mathew N, Diener HC, et al. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache 2009;49:216–26
   PubMed Web of Science ®Google Scholar
• Smith T, Dibernardo A, Shi Y, et al. Efficacy and safety of carisbamate in patients with diabetic neuropathy or postherpetic neuralgia: results from 3 randomized, double-blind placebo-controlled trials. Pain Pract 2014;14(4):332–42
   PubMed Web of Science ®Google Scholar
• Kulig K, Malawska B. Carisbamate, a new carbamate for the treatment of epilepsy. IDrugs 2007;10:720–7
   PubMed Web of Science ®Google Scholar
• Available from: http://www.medilexicon.com/drugs/horizant_1142.php [Accessed 19 March 2014]
   Google Scholar
• Vadivelu N, Mitra S, Narayan D. Recent advances in postoperative pain management. Yale J Biol Med 2010;83:11–25
   PubMedGoogle Scholar
• Merlino G, Serafini A, Lorenzut S, et al. Gabapentin enacarbil in restless legs syndrome. Drugs Today (Barc) 2010;46:3–11
   PubMed Web of Science ®Google Scholar
• Rauck R, Makumi CW, Schwartz S, et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract 2013;13:485–96
   PubMed Web of Science ®Google Scholar
• Meng FY, Zhang LC, Liu Y, et al. Efficacy and safety of gabapentin for treatment of post-herpetic neuralgia: a meta-analysis of randomized controlled trials. Minerva Anestesiol 2014;80(5):556–67
   PubMed Web of Science ®Google Scholar
• Ferzaz B, Brault E, Bourliaud G, et al. SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J Pharmacol Exp Ther 2002;301:1067–78
   PubMed Web of Science ®Google Scholar
• Leducq-Alet N, Vin V, Savi P, et al. TNF-alpha induced PMN apoptosis in whole human blood: protective effect of SSR180575, a potent and selective peripheral benzodiazepine ligand. Biochem Biophys Res Commun 2010;399:475–9
   PubMed Web of Science ®Google Scholar
• Available from: www.trialscentral.org/doseeffectofssr18-condtrid-267754.htm
   Google Scholar
• Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553–64
   PubMed Web of Science ®Google Scholar
• Available from: http://www.drugs.com/aptiom.html
   Google Scholar
• Stephen LJ, Brodie MJ. Pharmacotherapy of Epilepsy. CNS Drugs 2011;25:89–107
   PubMed Web of Science ®Google Scholar
• Available from: http://www.drugs.com/news/status-e2007-perampanel-development-program-8061.html
   Google Scholar
• Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/002434/WC500130815.pdf
   Google Scholar
• Maryanoff BE, Nortey SO, Gardocki JF, et al. Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds. J Med Chem 1987;30:880–7
   PubMed Web of Science ®Google Scholar
• Kramer CK, Leitão CB, Pinto LC, et al. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev 2011;12:e338–47
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des 2010;16:2103–12
   PubMed Web of Science ®Google Scholar
• Kampman KM, Pettinati HM, Lynch KG, et al. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 2013;133:94–9
   PubMed Web of Science ®Google Scholar
• Linde M, Mulleners WM, Chronicle EP, et al. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010610
   PubMed Web of Science ®Google Scholar
• Ferrari A, Tiraferri I, Neri L, et al. Clinical pharmacology of topiramate in migraine prevention. Expert Opin Drug Metab Toxicol 2011;7:1169–81
   PubMed Web of Science ®Google Scholar
• TOPIRAMATE (topiramate) tablet TOPIRAMATE (topiramate) tablet [Torrent Pharmaceuticals Limited]. DailyMed Torrent Pharmaceuticals Limited; 2011
   Google Scholar
• Topamax (Topiramate) Drug Information: Description, User Reviews, Drug Side Effects, Interactions - Prescribing Information at RxList. Rxlist.com. 2012-11-09. Retrieved 2014-03-23
   Google Scholar
• Boyd A, Casselini C, Vinik E, et al. Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate. J Diabetes Sci Technol 2011;5:714–22
   PubMedGoogle Scholar
• Raskin P, Donofrio PD, Rosenthal NR, et al. Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects. Neurology 2004;63:865–73
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Lunn MP, et al. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2013;8:CD008314
   PubMedGoogle Scholar
• Evgenov OV, Pacher P, Schmidt PM, et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755–68
   PubMed Web of Science ®Google Scholar
• Wingler K, Schmidt HHHW. Good stress, bad stress-the delicate balance in the vasculature. Dtsch Arztebl Int 2009;106:677–84
   PubMed Web of Science ®Google Scholar
• Zhou Z, Pyriochou A, Kotanidou A, et al. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol 2008;295:H1763–671
   PubMed Web of Science ®Google Scholar
• Durrani AI, Schwartz H, Nagl M, et al. Determination of free [alpha]-lipoic acid in foodstuffs by HPLC coupled with CEAD and ESI-MS. Food Chem 2010;120:38329–36
   Google Scholar
• Petersen Shay K, Moreau RF, Smith EJ, et al. Is alpha-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. IUBMB Life 2008;60:362–7
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Lipoic acid. [Retrieved 21 March 2014]
   Google Scholar
• Mijnhout GS, Kollen BJ, Alkhalaf A, et al. Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol 2012;2012:456279
   PubMedGoogle Scholar
• Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006;29:2365–70
   PubMed Web of Science ®Google Scholar
• Biewenga G, Haenen GR, Bast A. The role of lipoic acid in the treatment of diabetic polyneuropathy. Drug Metab Rev 1997;29:1025–54
   PubMed Web of Science ®Google Scholar
• Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995;19:227–50
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Stevens MJ, Raffel DM, et al. Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia 2013;56:1835–44
   PubMed Web of Science ®Google Scholar
• Cotter MA, Ekberg K, Wahren J, et al. Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003;52:1812–17
   PubMed Web of Science ®Google Scholar
• Ekberg K, Brismar T, Johansson BL, et al. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007;30:71–6
   PubMed Web of Science ®Google Scholar
• Sima AA, Zhang W, Grunberger G. Type 1 diabetic neuropathy and C-peptide. Exp Diabesity Res 2004;5:65–77
   PubMedGoogle Scholar
• Wahren J, Johansson BL, Wallberg-Henriksson H, et al. C-peptide revisited–new physiological effects and therapeutic implications. J Intern Med 1996;240:115–24
   PubMed Web of Science ®Google Scholar
• Kamiya H, Zhang W, Ekberg K, et al. C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes 2006;55:3581–7
   PubMed Web of Science ®Google Scholar
• Ekberg K, Brismar T, Johansson BL, et al. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes 2003;52:536–41
   PubMed Web of Science ®Google Scholar
• Ekberg K, Johansson BL. Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes. Exp Diabetes Res 2008;2008:457912
   PubMed Web of Science ®Google Scholar
• Available from: http://clinicaltrials.gov/show/NCT01079325
   Google Scholar
• Available from: http://investor.sangamo.com/releasedetail.cfm?ReleaseID=610157
   Google Scholar
• Available from: http://www.gene.com/media/press-releases/4875/1999-04-08/phase-iii-trial-with-nerve-growth-factor [Retrieved 06 May 2014]
   Google Scholar
• Adeghate E, Kalasz H, Veress G, et al. Medicinal chemistry of drugs used in diabetic cardiomyopathy. Curr Med Chem 2010;17:517–51
   PubMed Web of Science ®Google Scholar
• Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013;6:390–9
   PubMed Web of Science ®Google Scholar
• Tierney EF, Thurman DJ, Beckles GL, et al. Association of statin use with peripheral neuropathy in the U.S. population 40 years of age or older. J Diabetes 2013;5:207–15
   PubMed Web of Science ®Google Scholar
• Zangiabadi N, Shafiee K, Alavi KH, et al. Atorvastatin treatment improves diabetic polyneuropathy electrophysiological changes in non-insulin dependent diabetic patients: a double blind, randomized clinical trial. Minerva Endocrinol 2012;37:195–200
   PubMed Web of Science ®Google Scholar
• Cho YR, Lim JH, Kim MY, et al. Therapeutic effects of fenofibrate on diabetic peripheral neuropathy by improving endothelial and neural survival in db/db mice. PLoS One 2014;9(1):e83204
   PubMedGoogle Scholar
• Davis TM, Yeap BB, Davis WA, et al. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2008;51(4):562–6
   PubMed Web of Science ®Google Scholar
• Available from: http://www.newstatesman.com/business/pharmaceutical/epicept-reports-positive-results-of-phase-ii-diabetic-neuropathy-trial
   Google Scholar
• Lynch ME, Clark AJ, Sawynok J. A pilot study examining topical amitriptyline, ketamine, and a combination of both in the treatment of neuropathic pain. Clin J Pain 2003;19:323–8
   PubMed Web of Science ®Google Scholar
• Gewandter JS, Mohile SG, Heckler CE, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors. Support Care Cancer 2014;22(7):1807–14
   PubMed Web of Science ®Google Scholar
• Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352(9145):1978–81
   PubMed Web of Science ®Google Scholar
• Parving HH, Larsen M, Hommel E, et al. Effect of antihypertensive treatment on blood-retinal barrier permeability to fluorescein in hypertensive type 1 diabetic patients with background retinopathy. Diabetologia 1989;32:440–4
   PubMed Web of Science ®Google Scholar
• Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor Benzapril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939–45
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Lauria G, Iliev IP, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension 2011;58(5):776–83
   PubMed Web of Science ®Google Scholar
• Güloglu C, Orak M, Ustündag M, et al. Analysis of amitriptyline overdose in emergency medicine. Emerg Med J 2011;28:296–9
   PubMed Web of Science ®Google Scholar
• Mari F, Gualco B, Rensi R, et al. Acute massive pulmonary thromboembolism due to acute intoxication by duloxetine: a case report. Cardiovasc Toxicol 2012;12:258–62
   PubMed Web of Science ®Google Scholar
• Taylor R, Pergolizzi JV, Raffa RB. Tapentadol extended release for chronic pain patients. Adv Ther 2013;30:14–27
   PubMed Web of Science ®Google Scholar
• Fuzier R, Serres I, Guitton E, et al. Adverse drug reactions to gabapentin and pregabalin: a review of the French pharmacovigilance database. Drug Saf 2013;36:55–62
   PubMed Web of Science ®Google Scholar